Our news

Protocol Paper for MELD-ATG

09. December 2021

Antithymocyte globulin (ATG), Thymoglobuline, an immunosuppressive agent used in one of the INNODIA clinical trials, has recently shown promise in the treatment of new-onset T1D subjects aged 12–45 years. Further exploration in lower age groups is encouraged.

The study protocol Minimum effective low dose Anti-human Thymocyte Globulin (MELD-ATG), based on the INNODIA master protocol is out. Phase II, dose ranging, efficacy study of ATG within 6 weeks of diagnosis of #T1D, was accepted and published in BMJ open.